Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor + aspirin vs clopidogrel + aspirin for prevention of early neurological deterioration in high-risk nondisabling ischemic cerebrovascular disease
ChiCTR2300068509Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ticagrelor in ischemic stroke and transient ischaemic attack (TIA) (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Incidence of early neurological deterioration. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
ticagrelor
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on ChiCTR2300068509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068509.